Product news

Share this article:

Boehringer Ingelheim Pharmaceuticals announced that the FDA has granted full approval of Aptivus (tipranavir) capsules. The full approval of Aptivus based largely on 48-week analyses of the Phase III pivotal clinical studies known as the RESIST (Randomized Evaluation of Strategic Intervention in Multi-Drug ReSistant Patients with Tipranavir) trials. These trials comprise one of the largest study programs conducted in treatment-experienced HIV patients. The FDA granted accelerated approval to Aptivus in June 2005. Accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.